Roble, Belko & Company, Inc Biomarin Pharmaceutical Inc Call Options Transaction History
Roble, Belko & Company, Inc
- $634 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BMRN
# of Institutions
636Shares Held
178MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.46 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.24 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.21 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$893 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$674 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $11.9B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...